%0 Generic %A H., Imai %A K., Komine %A S., Takahashi %A K., Saijo %A Y., Okada %A A., Kobayashi %A A., Okita %A S., Chikamatsu %A Y., Kasahara %A M., Takahashi %A T., Oishi %A H., Shirota %A H., Shimodaira %A C., Ishioka %D 2016 %T Supplementary Material for: Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Efficacy_and_Safety_Assessment_of_Paclitaxel_in_Patients_with_Docetaxel-Resistant_Esophageal_Squamous_Cell_Carcinoma/4028808 %R 10.6084/m9.figshare.4028808.v1 %2 https://karger.figshare.com/ndownloader/files/6487383 %2 https://karger.figshare.com/ndownloader/files/6487386 %2 https://karger.figshare.com/ndownloader/files/6487389 %2 https://karger.figshare.com/ndownloader/files/6487392 %K Esophageal cancer %K Paclitaxel %K Docetaxel %K Cross-resistance %X
Background: Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Methods: Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment. Results: A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively. Conclusions: There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma. %I Karger Publishers